ME Therapeutics Holdings Inc.
METX
CNSX
| 05/31/2025 | 02/28/2025 | 11/30/2024 | 08/31/2024 | 05/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -55.73% | 83.97% | -15.56% | -30.08% | -15.31% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -34.93% | 32.50% | -16.26% | -18.88% | 3.57% |
| Operating Income | 34.93% | -32.50% | 16.26% | 18.88% | -3.57% |
| Income Before Tax | 30.93% | -30.81% | 12.81% | 20.98% | 91.85% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 30.93% | -30.81% | 12.81% | 20.98% | 91.85% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 30.93% | -30.81% | 12.81% | 20.98% | 91.85% |
| EBIT | 34.93% | -32.50% | 16.26% | 18.88% | -3.57% |
| EBITDA | 37.01% | -28.43% | 16.55% | 18.91% | -3.57% |
| EPS Basic | 41.38% | -15.56% | 18.69% | 51.35% | 94.92% |
| Normalized Basic EPS | 41.76% | -17.86% | 19.40% | -103.68% | 94.90% |
| EPS Diluted | 42.18% | 5.41% | 18.69% | 60.00% | 94.89% |
| Normalized Diluted EPS | 41.76% | -17.86% | 19.40% | -103.68% | 94.90% |
| Average Basic Shares Outstanding | 17.94% | 13.76% | 6.91% | 61.24% | 60.55% |
| Average Diluted Shares Outstanding | 17.94% | 13.76% | 6.91% | 61.24% | 60.55% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |